NISCH and Insulin resistance: Since I1R and I3R do not share similar ligand‐binding sites and I3R is a regulator of insulin secretion, the potential interaction of rilmenidine with the I3type imidazoline receptor might explain its effects on improved insulin resistance and, thus, glucose levels (Bousquet et al., 2020).